JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

2012134 citationsJournal Article

Authors

Timothy P. LaBranche · Pfizer (United States)

Michael I. Jesson · Pfizer (United States)

Smaail Radi · Pfizer (United States)

Chad Storer · Pfizer (United States)

Julia A. Guzova · Pfizer (United States)

Sheri L. Bonar · Pfizer (United States)

Janice Thompson ·

Abstract

These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast-mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Bone Metabolism and Diseases Spondyloarthritis Studies and Treatments

Publication Details

Published in: Arthritis & Rheumatism

Volume 64, Issue 11, pp. 3531-3542

DOI: 10.1002/art.34649

Field-Weighted Citation Impact: 6.72

Command Palette

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

Authors

Abstract

Topics & Keywords

Publication Details